Related Experiment Videos

Inhibition and induction of human cytochrome P450 (CYP) enzymes

O Pelkonen¹, J Mäenpää, P Taavitsainen

¹Department of Pharmacology and Toxicology, University of Oulu, Finland.

Xenobiotica; the Fate of Foreign Compounds in Biological Systems

|January 16, 1999

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.

Gynecologic oncology·2024

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.

British journal of cancer·2023

Expression Analysis of Platinum Sensitive and Resistant Epithelial Ovarian Cancer Patient Samples Reveals New Candidates for Targeted Therapies.

Translational oncology·2018

Future directions for monitoring and human health research for the Arctic Monitoring and Assessment Programme.

Global health action·2018

See all related articles